 |
144 Diseases |  |
5 Trials |
|
5 Trials |  |
861 News |  |
| «123456789» |
- | Jakafi oral (ruxolitinib) / Novartis, Incyte
Journal: Novel treatments to tackle myelofibrosis. (Pubmed Central) - Apr 28, 2019
Despite the dramatic progress made in the treatment of patients with myelofibrosis since the introduction of the JAK1/2 inhibitor ruxolitinib, a therapeutic option that can modify the natural history of the disease and prevent evolution to blast-phase is still lacking...Expert commentary: The most mature advances in treatment of myelofibrosis are the development of second-generation JAK1/2 inhibitors and improvements in expanding access to donors for transplantation. In addition, there are efforts to identify drugs that target pathways other than JAK/STAT signaling that might improve the survival of myelofibrosis patients, and limit the need for stem-cell transplantation.
- ||| imetelstat (JNJ-63935937) / Geron
$GERN up to $2.03.... Needs to stay above $2 resistance.... Many who bought back in at 99 cents going LONG now... #Imetelstat #BloodCancer @RonReblando @lavery1965 @DNABARCODE @BarbSabran #Biotech @JacobPlieth (Twitter) - Apr 11, 2019
- ||| imetelstat (JNJ-63935937) / Geron, luspatercept (ACE-536) / Celgene, Acceleron
I do think MDS - the marrow failure portion - has been neglected, and that’s where drugs like luspatercept, imetelstat may have a role. But once blasts start to accumulate, biology is more AML-like & it is arbitrary to exclude someone with 17% blasts from a trial but include 21%. (Twitter) - Apr 7, 2019
- || Venclexta (venetoclax) / Roche, AbbVie, imetelstat (JNJ-63935937) / Geron
Be supportive of the upcoming P3 trial of Imetelstat? Push for combo Imetelstat/Venetoclax trials? (Twitter) - Apr 6, 2019
- | imetelstat (JNJ-63935937) / Geron
@GeronCorp imetelstat (Twitter) - Mar 29, 2019
- | Rytelo (imetelstat) / Geron
Enrollment closed, Phase classification: IMerge: Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Feb 15, 2019
P2, N=225, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
In addition, there are efforts to identify drugs that target pathways other than JAK/STAT signaling that might improve the survival of myelofibrosis patients, and limit the need for stem-cell transplantation. Recruiting --> Active, not recruiting | Phase classification: P3 --> P2
- | Rytelo (imetelstat) / Geron
Trial completion date: Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor (clinicaltrials.gov) - Jan 18, 2019
P2, N=107, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting | Phase classification: P3 --> P2 Trial completion date: Apr 2019 --> Apr 2020
- | imetelstat (JNJ-63935937) / Geron
Review, Journal: Oligonucleotides Targeting Telomeres and Telomerase in Cancer. (Pubmed Central) - Dec 13, 2018
Specifically, GRN163L and T-oligos have demonstrated promising anticancer activity in multiple cancers types via induction of potent DNA damage responses...This review aims to provide a comprehensive understanding of current oligonucleotide-based anticancer therapies that target telomeres and telomerase. These studies may help design novel therapeutic approaches to overcome the challenges of oligonucleotide therapy in a clinical setting.
- | Rytelo (imetelstat) / Geron
Trial completion date: IMerge: Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Nov 16, 2018
P3, N=225, Recruiting, Sponsor: Janssen Research & Development, LLC
These studies may help design novel therapeutic approaches to overcome the challenges of oligonucleotide therapy in a clinical setting. Trial completion date: Oct 2021 --> Feb 2022
- | Rytelo (imetelstat) / Geron
Trial termination: Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors (clinicaltrials.gov) - Jul 20, 2018
P2, N=43, Terminated, Sponsor: Pediatric Brain Tumor Consortium
Trial completion date: Oct 2021 --> Feb 2022 Completed --> Terminated; Due to several intracranial hemorrhages and recommendation by the PBTC DSMB.
- | Rytelo (imetelstat) / Geron
Trial completion, Trial completion date, Trial primary completion date: Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis (clinicaltrials.gov) - Jul 20, 2018
P2, N=81, Completed, Sponsor: Janssen Research & Development, LLC
Completed --> Terminated; Due to several intracranial hemorrhages and recommendation by the PBTC DSMB. Active, not recruiting --> Completed | Trial completion date: Jan 2019 --> May 2018 | Trial primary completion date: Jan 2019 --> May 2018
- | Rytelo (imetelstat) / Geron
Trial completion date, Trial primary completion date: IMerge: Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Jul 13, 2018
P3, N=225, Recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed | Trial completion date: Jan 2019 --> May 2018 | Trial primary completion date: Jan 2019 --> May 2018 Trial completion date: Feb 2022 --> Oct 2021 | Trial primary completion date: Feb 2021 --> Oct 2020
- |||| Rytelo (imetelstat) / Geron
Trial completion date, Trial primary completion date: IMerge: Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Jun 29, 2018
P3, N=225, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Feb 2022 --> Oct 2021 | Trial primary completion date: Feb 2021 --> Oct 2020 Trial completion date: Oct 2021 --> Feb 2022 | Trial primary completion date: Oct 2020 --> Feb 2021
- |||| Rytelo (imetelstat) / Geron
Trial primary completion date: IMerge: Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - May 3, 2018
P3, N=225, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Oct 2021 --> Feb 2022 | Trial primary completion date: Oct 2020 --> Feb 2021 Trial primary completion date: Feb 2021 --> Oct 2020
- | Review, Journal: Developmental Therapeutics in Myeloproliferative Neoplasms. (Pubmed Central) - Apr 24, 2018
In polycythemia vera, a novel interferon administered every 2 weeks is being developed for front-line therapy in high-risk individuals, and inhibitors of human double minute 2 (HDM2) have shown promise in preclinical studies, as have HDAC inhibitors such as givinostat (both in the laboratory and in the clinic). Ruxolitinib is approved for second-line therapy of polycythemia vera and is being developed for essential thrombocythemia.
- ||| Rytelo (imetelstat) / Geron
Enrollment closed, Enrollment change: Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor (clinicaltrials.gov) - Apr 24, 2018
P2, N=107, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Ruxolitinib is approved for second-line therapy of polycythemia vera and is being developed for essential thrombocythemia. Suspended --> Active, not recruiting | N=160 --> 107
- | imetelstat (JNJ-63935937) / Geron
Biomarker, Preclinical, Journal: Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner. (Pubmed Central) - Dec 27, 2017
Likewise, in vivo imetelstat treatment caused tumor xenograft growth inhibition in a telomere-length dependent manner. We conclude from these preclinical studies of telomerase as an oncotarget tested by imetelstat response that imetelstat has efficacy across the entire oncogenotype spectrum of NSCLC, continuous therapy is necessary to prevent telomere regrowth, and short telomeres appears to be the best treatment biomarker.
- | imetelstat (JNJ-63935937) / Geron
Clinical, P2 data, Journal: A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study. (Pubmed Central) - Dec 25, 2017
Telomerase inhibition was observed in peripheral blood mononuclear cells (PBMCs) for at least 8 days. Imetelstat demonstrated intratumoral and PBMC target inhibition; the regimen proved too toxic in children with recurrent CNS tumors.
- |||| Rytelo (imetelstat) / Geron
Trial primary completion date: IMerge: Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Oct 23, 2017
P3, N=225, Recruiting, Sponsor: Janssen Research & Development, LLC
Imetelstat demonstrated intratumoral and PBMC target inhibition; the regimen proved too toxic in children with recurrent CNS tumors. Trial primary completion date: Apr 2019 --> Feb 2021
- || imetelstat (GRN163L) / Geron
Trial primary completion date: Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis (clinicaltrials.gov) - Jun 20, 2017
P2, N=81, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Apr 2019 --> Feb 2021 Trial primary completion date: May 2017 --> Jan 2019
- | imetelstat (JNJ-63935937) / Geron
Biomarker, Journal: Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS. (Pubmed Central) - May 18, 2017
The activity of the telomerase inhibitor, imetelstat, was measured using leukaemia cell lines...AML cell lines and primary blasts harbour distinct TERTpro/Ex1 methylation profiles that could serve as a prognostic biomarker of AML. However, validation in a large cohort of patients is necessary to confirm our findings.
- Rytelo (imetelstat) / Geron
Trial primary completion date: Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor (clinicaltrials.gov) - Nov 1, 2016
P2, N=160, Suspended, Sponsor: Janssen Research & Development, LLC
However, validation in a large cohort of patients is necessary to confirm our findings. Trial primary completion date: Nov 2017 --> May 2018
- |||| imetelstat (JNJ-63935937) / Geron
Clinical: MDS3001: Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Oct 25, 2016
P3, N=200, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Nov 2017 --> May 2018 Trial primary completion date: Jun 2018 --> Apr 2019
- | Rytelo (imetelstat) / Geron
Enrollment change, Trial suspension: Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor (clinicaltrials.gov) - Oct 11, 2016
P2, N=160, Suspended, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Jun 2018 --> Apr 2019 N=200 --> 160 | Recruiting --> Suspended
- Rytelo (imetelstat) / Geron
Trial completion: Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors (clinicaltrials.gov) - Apr 12, 2016
P2, N=43, Completed, Sponsor: Pediatric Brain Tumor Consortium
N=200 --> 160 | Recruiting --> Suspended Active, not recruiting --> Completed
- || Rytelo (imetelstat) / Geron
Trial primary completion date: Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor (clinicaltrials.gov) - Mar 8, 2016
P2, N=200, Recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Trial primary completion date: Mar 2017 --> Nov 2017
- |||| imetelstat (JNJ-63935937) / Geron
Clinical: MDS3001: Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Mar 4, 2016
P3, N=200, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Mar 2017 --> Nov 2017 Trial primary completion date: Mar 2018 --> Jun 2018
- |||||| Rytelo (imetelstat) / Geron
Enrollment open: IMerge: Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Dec 5, 2015
P3, N=200, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Mar 2018 --> Jun 2018 Not yet recruiting --> Recruiting
- ||| imetelstat (GRN163L) / Geron
Enrollment closed: Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis (clinicaltrials.gov) - Nov 15, 2015
P2, N=81, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||||||||| Rytelo (imetelstat) / Geron
New P3 trial: IMerge: Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Nov 8, 2015
P3, N=200, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- Herceptin (trastuzumab) / Roche
Trial completion: A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer (clinicaltrials.gov) - Oct 27, 2015
P1, N=10, Completed, Sponsor: Indiana University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| imetelstat (GRN163L) / Geron
Enrollment open, Enrollment change: Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis (clinicaltrials.gov) - Sep 24, 2015
P2, N=80, Recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Active, not recruiting --> Recruiting | N=56 --> 80
- Rytelo (imetelstat) / Geron
Enrollment open, Trial primary completion date: Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor (clinicaltrials.gov) - Jul 16, 2015
P2, N=200, Recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Recruiting | N=56 --> 80 Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2018 --> Mar 2017
- ||| imetelstat (GRN163L) / Geron
Phase classification, Enrollment change, Trial primary completion date: Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis (clinicaltrials.gov) - Jun 20, 2015
P2, N=56, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2018 --> Mar 2017 Phase classification: P=N/A --> P2 | N=80 --> 56 | Trial primary completion date: Sep 2015 --> Mar 2017
- ||||| Rytelo (imetelstat) / Geron
New P2 trial: Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor (clinicaltrials.gov) - Apr 25, 2015
P2, N=200, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- ||| Rytelo (imetelstat) / Geron
Enrollment change: Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Apr 21, 2015
P2, N=116, Completed, Sponsor: Geron Corporation
Phase classification: P=N/A --> P2 | N=80 --> 56 | Trial primary completion date: Sep 2015 --> Mar 2017 N=96 --> 116
- | Rytelo (imetelstat) / Geron
Trial completion, Enrollment change, Trial primary completion date: Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera (clinicaltrials.gov) - Apr 21, 2015
P2, N=20, Completed, Sponsor: Geron Corporation
N=96 --> 116 Active, not recruiting --> Completed | N=40 --> 20 | Trial primary completion date: Jan 2014 --> Oct 2013
- | Rytelo (imetelstat) / Geron
Trial completion, Enrollment change: Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma (clinicaltrials.gov) - Mar 11, 2015
P2, N=13, Completed, Sponsor: Geron Corporation
Active, not recruiting --> Completed | N=40 --> 20 | Trial primary completion date: Jan 2014 --> Oct 2013 Active, not recruiting --> Completed | N=48 --> 13
- | Rytelo (imetelstat) / Geron
Enrollment closed: Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera (clinicaltrials.gov) - Nov 13, 2014
P2, N=40, Active, not recruiting, Sponsor: Geron Corporation
Active, not recruiting --> Completed | N=48 --> 13 Suspended --> Active, not recruiting
- Rytelo (imetelstat) / Geron
Enrollment closed, Enrollment change: Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors (clinicaltrials.gov) - Oct 28, 2014
P2, N=43, Active, not recruiting, Sponsor: Pediatric Brain Tumor Consortium
Suspended --> Active, not recruiting Recruiting --> Active, not recruiting | N=90 --> 43
- || imetelstat (GRN163L) / Geron
Enrollment change, Trial primary completion date: Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=80, Active, not recruiting, Sponsor: Geron Corporation
Recruiting --> Active, not recruiting | N=90 --> 43 N=40 --> 80 | Trial primary completion date: Jan 2015 --> Sep 2015
- Rytelo (imetelstat) / Geron
Trial primary completion date: Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma (clinicaltrials.gov) - Aug 15, 2014
P2, N=48, Active, not recruiting, Sponsor: Geron Corporation
N=40 --> 80 | Trial primary completion date: Jan 2015 --> Sep 2015 Trial primary completion date: Dec 2013 --> Dec 2014
- imetelstat (GRN163L) / Geron
Trial primary completion date: Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis (clinicaltrials.gov) - Jul 30, 2014
P=N/A, N=40, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Dec 2013 --> Dec 2014 Trial primary completion date: Jan 2014 --> Jan 2015
- Rytelo (imetelstat) / Geron
Trial initiation date: Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Jun 2, 2014
P2, N=0, Withdrawn, Sponsor: Children's Oncology Group
Trial primary completion date: Jan 2014 --> Jan 2015 Initiation date: Jan 2014 --> Jun 2014
- Rytelo (imetelstat) / Geron
Trial suspension: Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera (clinicaltrials.gov) - Mar 23, 2014
P2, N=40, Suspended, Sponsor: Geron Corporation
Initiation date: Jan 2014 --> Jun 2014 Active, not recruiting --> Suspended
- Rytelo (imetelstat) / Geron
Trial withdrawal: Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Mar 6, 2014
P2, N=0, Withdrawn, Sponsor: Children's Oncology Group
Active, not recruiting --> Suspended Not yet recruiting --> Withdrawn
- Rytelo (imetelstat) / Geron
Enrollment change: Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Mar 6, 2014
P2, N=0, Withdrawn, Sponsor: Children's Oncology Group
Not yet recruiting --> Withdrawn N=110 --> 0
- Rytelo (imetelstat) / Geron
Enrollment open: Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors (clinicaltrials.gov) - Feb 19, 2014
P2, N=90, Recruiting, Sponsor: Pediatric Brain Tumor Consortium
N=110 --> 0 Suspended --> Recruiting
- ||| imetelstat (GRN163L) / Geron
Trial completion: Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies (clinicaltrials.gov) - Feb 17, 2014
P1, N=85, Completed, Sponsor: Geron Corporation
Suspended --> Recruiting Active, not recruiting --> Completed
- | Rytelo (imetelstat) / Geron
Trial completion: Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD) (clinicaltrials.gov) - Feb 17, 2014
P1, N=48, Completed, Sponsor: Geron Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed